Get started
Author

Elisa Civanelli

Observed name: E. Civanelli
ORCID: 0000-0001-5427-8372
Observed ORCID: 0000-0001-5427-8372
OpenAlex ID: A5037565739
P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors
2020 · Andrea Romagnani, Elsa Rottoli, et al. · Cancer Research · 62
PDF
IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
2023 · Zoë Johnson, Chiara Tarantelli, et al. · Cancer Research Communications · 32
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors
2021 · Afua Adjeiwaa Mensah, Filippo Spriano, et al. · Blood Advances · 22
PDF
Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
2024 · Lodovico Terzi Di Bergamo, Gabriela Forestieri, et al. · Blood · 4
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
2025 · Binu Kandathilparambil Sasi, Chiara Tarantelli, et al. · Haematologica · 3
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype
2025 · Chiara Tarantelli, Omar Kayali, et al. · Hematological Oncology · 3
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas
2025 · Chiara Tarantelli, Filippo Spriano, et al. · Cancers · 2
PDF
Highly Selective Allosteric Modulator of the Phosphoinositide 3‐Kinase Delta (PI3Kδ) Roginolisib In Patients With Refractory/Relapsed Follicular Lymphoma
2023 · C. Carlo‐Stella, C. Tarantelli, et al. · Hematological Oncology · 2
PDF
Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclax
2025 · Alberto J. Arribas, Elisa Civanelli, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
115 | the Btk Degrader Bgb‐16673 and the Bcl2 Inhibitor Sonrotoclax Shows Anti‐tumor Activity as Single Agents and in Combination in Marginal Zone Lymphoma Models
2025 · A. J. Arribas, E. Civanelli, et al. · Hematological Oncology · 1
PDF
Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies
2023 · Binu Kandathilparambil Sasi, Chiara Tarantelli, et al. · Blood · 1
Non-ATP competitive inhibition of PI3Kδ with IOA-244 shows anti-lymphoma activity
2022 · C. Tarantelli, F. Spriano, et al. · European Journal of Cancer · 1
PDF
BTK/BCL2 dual targeting enhances apoptosis in marginal zone lymphoma: preclinical activity of tacabrutideg (BGB-16673) and sonrotoclax
2026 · Alberto J. Arribas, Alex Zadro, et al. · Haematologica
PDF
Surface expression of ROR1 across lymphoma cell lines identifies models for preclinical evaluation of ROR1-targeting antibody-drug conjugates
2026 · Chiara Tarantelli, Elisa Civanelli, et al. · Leukemia & lymphoma/Leukemia and lymphoma
Ibrutinib modulates CD19 expression and improves efficacy of CD19-CAR T cells in B-cell lymphoma models
2026 · Sisi Wang, Alberto J Arribas, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies
2026 · Filippo Spriano, Alberto J. Arribas, et al. · eJHaem
Characterization of lymphoma models for the surface ROR1 expression
2025 · Chiara Tarantelli, Elisa Civanelli, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract C023: Development of isogenic models of marginal zone lymphoma for therapeutic target discovery in TET2-deficient disease
2025 · Fangwen Zhang, Luciano Cascione, et al. · Molecular Cancer Therapeutics
Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B‐Cells Diffuse Large B‐Cell Lymphoma
2025 · Laurence K. Jennings, Filippo Spriano, et al. · ChemBioChem
PDF
Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models
2025 · Laura Barnabei, Alberto J. Arribas, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models.
2025 · Chiara Tarantelli, Filippo Spriano, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract 1878: Profiling protein-protein interactions to predict sensitivity to drugs targeting BCL2 family members in lymphoma models
2025 · Alberto J. Arribas, Byungsan Choi, et al. · Cancer Research
Abstract 410: The BTK degrader BGB-16673 shows anti-tumor activity in marginal zone lymphoma models
2025 · Alberto J. Arribas, Elisa Civanelli, et al. · Cancer Research
Author response for "Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype"
2025 · Chiara Tarantelli, Omar Kayali, et al.
Author response for "Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype"
2024 · Chiara Tarantelli, Omar Kayali, et al.
Works count: 74
Citation count: 134
H-index: 4
I10-index: 3
Year
Topic
Type